SIH Partners LLLP Acquires New Position in Indivior PLC (NASDAQ:INDV)

SIH Partners LLLP bought a new position in Indivior PLC (NASDAQ:INDV - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 217,058 shares of the company's stock, valued at approximately $2,698,000. SIH Partners LLLP owned 0.16% of Indivior as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in INDV. Claret Asset Management Corp bought a new stake in shares of Indivior during the 4th quarter valued at about $9,304,000. CenterBook Partners LP lifted its stake in shares of Indivior by 105.5% in the fourth quarter. CenterBook Partners LP now owns 1,147,841 shares of the company's stock worth $14,268,000 after buying an additional 589,158 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Indivior by 659.7% in the 4th quarter. Marshall Wace LLP now owns 506,782 shares of the company's stock worth $6,299,000 after purchasing an additional 440,072 shares in the last quarter. Kazazian Asset Management LLC bought a new stake in shares of Indivior in the 4th quarter worth $1,706,000. Finally, Hennion & Walsh Asset Management Inc. bought a new stake in shares of Indivior in the 4th quarter worth $1,192,000. Hedge funds and other institutional investors own 60.33% of the company's stock.

Indivior Trading Up 7.4 %

Shares of INDV stock traded up $0.80 during trading hours on Friday, reaching $11.56. 1,463,302 shares of the company's stock were exchanged, compared to its average volume of 970,409. Indivior PLC has a 1 year low of $7.33 and a 1 year high of $18.59. The stock has a market cap of $1.59 billion, a PE ratio of -33.03 and a beta of 0.93. The stock's fifty day moving average price is $9.48 and its two-hundred day moving average price is $10.34.

Indivior (NASDAQ:INDV - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.41 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $0.19. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The company had revenue of $266.00 million during the quarter, compared to the consensus estimate of $240.13 million. On average, equities analysts expect that Indivior PLC will post 1.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

INDV has been the subject of several research analyst reports. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on Indivior in a research report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 target price on the stock. Finally, Piper Sandler decreased their target price on Indivior from $16.00 to $13.00 and set an "overweight" rating on the stock in a research report on Thursday, March 6th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.